A George Church spinout fighting the viral vector bottleneck in cell and gene therapy lands $55M

Josh Sullivan

A synthetic biology company spun out of George Church’s lab is set to tackle the gene therapy manufacturing bottleneck, and it just landed $55 million …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A George Church spinout fighting the viral vector bottleneck in cell and gene therapy lands $55M

Josh Sullivan

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Daiichi Sankyo finds successor to late R&D exec; Versant, Novartis' kidney biotech poaches Sana CBO

A George Church spin­out fight­ing the vi­ral vec­tor bot­tle­neck in cell and gene ther­a­py lands $55M

Josh Sullivan

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Dai­ichi Sankyo finds suc­ces­sor to late R&D ex­ec; Ver­sant, No­var­tis' kid­ney biotech poach­es Sana CBO

A George Church spinout fighting the viral vector bottleneck in cell and gene therapy lands $55M

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Daiichi Sankyo finds successor to late R&D exec; Versant, Novartis' kidney biotech poaches Sana CBO